{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-039352","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.397275+00:00","generated_at":"2026-05-15T07:50:01.148858+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Silo Pharma acquires QwikAgents software and domains for 2.1M shares","bullets":["Asset purchase agreement with Many Ads Inc. for QwikAgents web application and domain names (qwikagents.com, .ai, .co).","Consideration: 2,100,000 unregistered shares of Silo Pharma common stock, issued under Section 4(a)(2) exemption.","Agreement includes customary representations, warranties, and indemnification provisions; liability capped at Purchase Price.","Software includes Next.js/React portal and MCP server; open-source components disclosed (LGPL dependency noted).","Transaction closed on March 30, 2026; domain transfer pending registrar processing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-039352","json":"https://secwatch.observer/filing/0001213900-26-039352.json","markdown":"https://secwatch.observer/filing/0001213900-26-039352.md","text":"https://secwatch.observer/filing/0001213900-26-039352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/ea0284319-8k_silo.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:50:01.148858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f87e89ae9d166bc7394bcfa0f3cf022a2973375","claim":"Silo Pharma, Inc. entered into Agreement with Many Ads Inc. (effective 2025-07-29).","evidence_excerpt":"On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-063827","ticker":"LOKV","company_name":"Live Oak Acquisition Corp. V","filed_at":"2026-06-02T13:09:00+00:00","headline":"Live Oak enters forward purchase agreement to reduce redemptions for Teamshares merger","event_type":"m_and_a","sec_items":["1.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063827","json":"https://secwatch.observer/filing/0001213900-26-063827.json","markdown":"https://secwatch.observer/filing/0001213900-26-063827.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2048951/000121390026063827/0001213900-26-063827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2048951/000121390026063827/ea0293178-8ka425_liveoak5.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm","comparable_excerpt":"On June 1, 2026, Live Oak Acquisition Corp. V, a Cayman Island exempted company (“ Live Oak ”), and a fund sub-advised by JBA Asset Management LLC (“ Seller ” or “ FPA Investor ”) entered into an agreement (the “ Forward Purchase Agreement ”) for an OTC Prepaid Share Forward Transaction-Optional Early Termination","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2048951/000121390026063827/0001213900-26-063827-index.htm"}},{"accession":"0001738827-26-000023","ticker":"KLXE","company_name":"KLX Energy Services Holdings, Inc.","filed_at":"2026-06-02T21:14:16+00:00","headline":"KLX Energy acquires Wolfpack assets for $17M; also exchanges $2.19M notes for equity","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: m_and_a"],"urls":{"canonical":"https://secwatch.observer/filing/0001738827-26-000023","json":"https://secwatch.observer/filing/0001738827-26-000023.json","markdown":"https://secwatch.observer/filing/0001738827-26-000023.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738827/000173882726000023/0001738827-26-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738827/000173882726000023/klxe-20260602.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm","comparable_excerpt":"Purchase and Sale Agreement On June 2, 2026 (the “Closing Date”), KLX Energy Services Holdings, Inc., a Delaware corporation (the “Company”), completed the acquisition (the “Acquisition”) of certain assets owned by Wolf Pack Rentals, LLC, a Texas limited liability company (“Wolf Pack” or the “Seller”), pursuant to that certain asset purchase agreement, dated June 2, 2026 , by and among Wolf Pack, KLX Energy Services LLC, a Delaware limited liability company and indirect wholly owned subsidiary of the Company (the “Buyer”), the Company and, solely for purposes of Section 8.05 thereto, Stevie Cooper and Stewart Cooper (the “Purchase Agreement”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1738827/000173882726000023/0001738827-26-000023-index.htm"}},{"accession":"0001104659-26-069515","ticker":"XRN","company_name":"Chiron Real Estate Inc.","filed_at":"2026-06-02T20:30:45+00:00","headline":"Chiron Real Estate closes $249M acquisition of two senior housing communities; issues $100M Series C preferred","event_type":"m_and_a","sec_items":["1.01","2.01","2.03","3.02","3.03","5.03","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: m_and_a"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069515","json":"https://secwatch.observer/filing/0001104659-26-069515.json","markdown":"https://secwatch.observer/filing/0001104659-26-069515.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926069515/0001104659-26-069515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926069515/tm2616685d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm","comparable_excerpt":"Item 1.01 Entry into a Material Definitive Agreement Seventh Amendment to the Agreement of Limited Partnership of Chiron Real Estate LP On May 28, 2026, Chiron Real Estate Inc. (the “ Company ”), as the sole member of the general partner of Chiron Real Estate LP (the “ Operating Partnership ”), entered into an amendment to the agreement of limited partnership of the Operating Partnership (the “ OP Amendment ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926069515/0001104659-26-069515-index.htm"}},{"accession":"0001158172-26-000042","ticker":"SCOR","company_name":"COMSCORE, INC.","filed_at":"2026-06-02T21:12:38+00:00","headline":"comScore sells Movies Business for $70M cash to Advaya Capital affiliate; repays $40.1M debt","event_type":"m_and_a","sec_items":["1.01","1.02","2.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: m_and_a"],"urls":{"canonical":"https://secwatch.observer/filing/0001158172-26-000042","json":"https://secwatch.observer/filing/0001158172-26-000042.json","markdown":"https://secwatch.observer/filing/0001158172-26-000042.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158172/000115817226000042/0001158172-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158172/000115817226000042/scor-20260527.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm","comparable_excerpt":"On May 27, 2026, comScore, Inc. (the \"Company\"), entered into an Equity Purchase Agreement (the \"Purchase Agreement\") with an affiliate of Advaya Capital, Flix Buyer Inc. (the \"Purchaser\"), pursuant to which the Company sold its box office measurement, reporting and analytics business and its Hollywood Software business (collectively, the \"Movies Business\"), including 100% of the interests of Rentrak, LLC (\"Rentrak\"), an Oregon limited liability company and wholly owned subsidiary of the Company, to the Purchaser for an aggregate base purchase price of $70.0 million in cash, subject to customary adjustments and other terms as more fully set forth in the Purchase Agreement (the \"Transaction\").","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1158172/000115817226000042/0001158172-26-000042-index.htm"}},{"accession":"0001104659-26-069483","ticker":"ISRLF","company_name":"Israel Acquisitions Corp","filed_at":"2026-06-02T20:15:53+00:00","headline":"Israel Acquisitions Corp extends Gadfin deal deadline to June 15, 2026","event_type":"m_and_a","sec_items":["1.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: m_and_a"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069483","json":"https://secwatch.observer/filing/0001104659-26-069483.json","markdown":"https://secwatch.observer/filing/0001104659-26-069483.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1915328/000110465926069483/0001104659-26-069483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1915328/000110465926069483/tm2616068d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm","comparable_excerpt":"On May 31, 2026, the Company, Gadfin, and Gadfin Regev Holdings Ltd., a company domiciled in Israel, entered into a sixth amendment to the BCA (the “ Sixth BCA Amendment ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1915328/000110465926069483/0001104659-26-069483-index.htm"}},{"accession":"0001493152-26-026878","ticker":"HVII","company_name":"Hennessy Capital Investment Corp. VII","filed_at":"2026-06-02T20:15:28+00:00","headline":"HVII extends business combination with ONE Nuclear to August 15, 2026; increases promissory note to $317K","event_type":"m_and_a","sec_items":["1.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: m_and_a"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026878","json":"https://secwatch.observer/filing/0001493152-26-026878.json","markdown":"https://secwatch.observer/filing/0001493152-26-026878.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1846416/000149315226026878/0001493152-26-026878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1846416/000149315226026878/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm","comparable_excerpt":"(ii) the maturity date of the Promissory Note from June 30, 2026 to August 15, 2026 and (b) increases the maximum aggregate principal amount of loan advances under the Promissory Note from $300,000 to $316,975.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1846416/000149315226026878/0001493152-26-026878-index.htm"}},{"accession":"0000107140-26-000034","ticker":"WLY","company_name":"JOHN WILEY & SONS, INC.","filed_at":"2026-06-02T12:30:39+00:00","headline":"Wiley acquires Emerald Publishing for $452M; adds ~500 journals, expected accretive in year one","event_type":"m_and_a","sec_items":["1.01","2.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: m_and_a"],"urls":{"canonical":"https://secwatch.observer/filing/0000107140-26-000034","json":"https://secwatch.observer/filing/0000107140-26-000034.json","markdown":"https://secwatch.observer/filing/0000107140-26-000034.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/107140/000010714026000034/0000107140-26-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/107140/000010714026000034/jwa-20260601.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm","comparable_excerpt":"entered into an Equity Purchase Agreement (the \"Purchase Agreement\") with CIG Emerald Midco LLC, a Delaware limited liability company (the \"Seller\"), and CIG Emerald Holding LLC, a Delaware limited liability company (\"Emerald Holding\"), pursuant to which Buyer acquired from the Seller all of the issued and outstanding equity securities of Emerald Holding (the \"Transaction\") in exchange for GBP £337.5 million (approximately $452 million)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/107140/000010714026000034/0000107140-26-000034-index.htm"}},{"accession":"0001193125-26-252474","ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-06-02T11:05:07+00:00","headline":"Travere licenses Everest's BTK inhibitor with $112.5M upfront, up to $1.03B milestones","event_type":"m_and_a","sec_items":["1.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: m_and_a"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252474","json":"https://secwatch.observer/filing/0001193125-26-252474.json","markdown":"https://secwatch.observer/filing/0001193125-26-252474.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/0001193125-26-252474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/d107618d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm","comparable_excerpt":"On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/0001193125-26-252474-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}